Clinical Trials Logo

Recurrent Childhood Brain Tumor clinical trials

View clinical trials related to Recurrent Childhood Brain Tumor.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03860376 Completed - Clinical trials for Recurrent Childhood Acute Lymphoblastic Leukemia

Ex Vivo Drug Sensitivity Testing and Mutation Profiling

Start date: February 21, 2019
Phase:
Study type: Observational

This study is a prospective, non-randomized feasibility study. Freshly isolated tumor cells from patients will be screened using state-of-the-art viability assay designed for ex vivo high-throughput drug sensitivity testing (DST). In addition, genetic information will be obtained from cancer and normal (germline) tissue and correlated with drug response. This study will provide the platform for informing treating physician about individualized treatment options. The main outcome of this study will be the proportions of the patients whose treatment was guided by the personalized medicine approach.

NCT ID: NCT00946335 Completed - Clinical trials for Recurrent Childhood Ependymoma

ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors

Start date: July 2009
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of ABT-888 when given in combination with temozolomide in treating young patients with recurrent or refractory CNS tumors. ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving ABT-888 together with temozolomide may kill more tumor cells.

NCT ID: NCT00679354 Completed - Clinical trials for Recurrent Childhood Cerebellar Astrocytoma

Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

Start date: June 2008
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well cilengitide works in treating younger patients with recurrent or progressive high-grade glioma that has not responded to standard therapy. Cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor.

NCT ID: NCT00363272 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma

Start date: June 2006
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of ispinesib in treating young patients with relapsed or refractory solid tumors or lymphoma. Drugs used in chemotherapy, such as ispinesib, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing

NCT ID: NCT00100880 Completed - Clinical trials for Recurrent Childhood Ependymoma

Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors

Start date: November 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with recurrent, progressive, or refractory CNS tumors. Lenalidomide may stop the growth of CNS tumors by blocking blood flow to the tumor. It may also stimulate the immune system in different ways and stop tumor cells from growing.

NCT ID: NCT00077454 Completed - Clinical trials for Recurrent Neuroblastoma

Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors

Start date: February 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of erlotinib when given with temozolomide in treating young patients with recurrent or refractory solid tumors. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving erlotinib with temozolomide may kill more tumor cells.

NCT ID: NCT00063973 Completed - Clinical trials for Recurrent Childhood Ependymoma

Cilengitide in Treating Children With Refractory Primary Brain Tumors

Start date: July 2003
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of cilengitide in treating children with recurrent, progressive, or refractory primary CNS tumors. Cilengitide may slow the growth of brain cancer cells by stopping blood flow to the tumor.